Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint

Renaissance 3 study found that adding TC-5214 to SSRI/SNRI therapy for eight weeks failed to change MADRS score.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »